Abstract
Five children with human immunodeficiency virus type-1 (HIV-1) infection, aged 4 to 13 years, manifested extrapyramidal dysfunction characterized by rigidity/stiffness, ambulation difficulties/shuffling gait, dysarthria/drooling/swallowing dysfunction, hypomimetic/inexpressive facies, and bradykinesia. Levodopa therapy caused an initial improvement in all symptoms, and the effect was sustained in most patients. Levodopa is a useful adjunctive therapy in HIV-1 infected children with extrapyramidal syndromes, by enhancing motor function and improving their quality of life.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1583-1585 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 47 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1996 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Clinical Neurology
Fingerprint
Dive into the research topics of 'Levodopa therapy improves motor function in HIV-infected children with extrapyramidal syndromes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver